# Myriad Genetics (MYGN) — Analyst Forecast

MYGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mygn/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 1 | 5 | 3 | 9 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $2.00 | $4.02 | $8.00 | 6 |

Last price $4.35 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 13, 2026 | TD Cowen | Maintained | Hold | $4.50 |
| Oct 2, 2026 | Craig-Hallum | Maintained | Buy | $8.00 |
| Sep 9, 2026 | UBS | Maintained | Neutral | $3.60 |
| Sep 1, 2026 | Piper Sandler | Downgraded | Overweight → Underweight | $2.00 |
| Aug 18, 2026 | Stephens & Co. | Maintained | Equal-Weight | $3.00 |
| Aug 3, 2026 | Wells Fargo | Maintained | Equal-Weight | $3.00 |
| Jul 31, 2026 | TD Cowen | Maintained | Hold | $4.00 |
| May 6, 2026 | Wells Fargo | Maintained | Equal-Weight | $5.50 |
| May 6, 2026 | TD Cowen | Maintained | Hold | $6.00 |
| Feb 24, 2026 | UBS | Maintained | Neutral | $6.00 |
| Feb 24, 2026 | Wells Fargo | Maintained | Equal-Weight | $6.00 |
| Nov 11, 2025 | Piper Sandler | Maintained | Overweight | $8.50 |
| Nov 5, 2025 | Wells Fargo | Maintained | Equal-Weight | $6.50 |
| Nov 4, 2025 | UBS | Maintained | Neutral | $8.00 |
| Nov 4, 2025 | TD Cowen | Maintained | Hold | $9.00 |
| May 21, 2025 | Scotiabank | Downgraded | Sector Outperform → Sector Perform | $6.00 |
| May 15, 2025 | Piper Sandler | Maintained | Overweight | $9.00 |
| May 8, 2025 | Wells Fargo | Downgraded | Overweight → Equal-Weight | $6.00 |
| May 7, 2025 | Raymond James | Maintained | Outperform | $10.00 |
| May 7, 2025 | UBS | Maintained | Neutral | $7.00 |

## Frequently Asked Questions

### What is the price target for MYGN stock?

The average 12-month analyst price target for Myriad Genetics (MYGN) is $4.02, with a high estimate of $8.00 and a low of $2.00, across 6 analysts.

### Is MYGN a buy, sell, or hold?

Analysts covering Myriad Genetics currently average a Hold rating: 1 buy, 5 hold and 3 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for MYGN?

The average price target of $4.02 implies 7.66% downside from the last price of $4.35.

### What is the latest analyst rating on MYGN?

On Oct 13, 2026, TD Cowen maintained Myriad Genetics at Hold with a price target of $4.50.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).